CND Life Sciences offers the Syn-One Test®, a skin biopsy-based diagnostic tool that quantifies phosphorylated alpha-synuclein to assist in the diagnosis of synucleinopathies, including Parkinson's disease. This evidence-based test provides clinicians with over 95% sensitivity and specificity, addressing the challenge of accurately diagnosing these complex neurodegenerative disorders.
Funding
$15.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Diagnosing synucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy, is challenging due to overlapping symptoms and the lack of definitive diagnostic tools. This often leads to delayed or inaccurate diagnoses, hindering timely intervention and appropriate patient management.
Solution
CND Life Sciences offers the Syn-One Test®, a minimally invasive skin biopsy-based test that enables clinicians to visualize and quantify phosphorylated alpha-synuclein (P-SYN) in cutaneous nerve fibers. The test utilizes immunohistochemical staining of skin biopsy tissue, with double immunostaining for axonal fibers (PGP 9.5) and P-SYN. This allows for objective pathological insights into synucleinopathies, where abnormal deposition of misfolded alpha-synuclein protein occurs not only in the central nervous system but also in peripheral tissues like the skin. The Syn-One Test aids in differentiating between various synucleinopathies and other neurological disorders, providing clinicians with valuable information to support a more accurate and timely diagnosis.
Target Audience
The primary target audience includes neurologists, primary care physicians, and geriatricians seeking to improve diagnostic accuracy in patients suspected of having Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, or pure autonomic failure.
Features
- Minimally invasive 3mm skin biopsy procedure performed in-office
- Immunohistochemical staining and visualization of phosphorylated alpha-synuclein (P-SYN) in cutaneous nerve fibers
- Double immunostaining of skin biopsy tissue for axonal fibers (PGP 9.5) and P-SYN
- High sensitivity and specificity (>95%) across synucleinopathies, as demonstrated in the Synuclein-One Study published in JAMA
- Objective pathological insights aiding in the differentiation of synucleinopathies from other neurological disorders
- CLIA-certified and CAP-accredited pathology lab
- Digital pathology methods for slide interpretation